Thursday, August 24, 2017
Theragnostics, Ltd., a radiopharmaceuticals company developing products for the diagnosis and treatment of cancer, announced a mutual distribution and manufacturing agreement with ROTOP Pharmaka GmbH, covering select products in the Companies' respective markets. Theragnostics also announced the opening of its U.S. headquarters, Theragnostics, Inc., in Boston, Mass. and the commencement of commercial operations.
Under the agreement, Theragnostics will distribute select ROTOP products in the U.S., Canada, Australia and New Zealand. In addition, ROTOP will manufacture GalliProst®, Theragnostics' lead imaging candidate, and other agents in development, with distribution rights in the European Union and Switzerland. Information about the products available through Theragnostics may be found at Theragnostics.com/products.
"Our relationship with ROTOP reflects our mission to serve the nuclear medicine community by delivering precisely targeted imaging and therapy agents for cancer patients and others," said Patrick Donahue, CEO, Theragnostics, Inc. "It also supports our strategy to build revenue alongside the clinical development of our proprietary Galli® platform, which we believe will expand the power of PET imaging for thousands of physicians."
Theragnostics' new U.S. headquarters is located in the historic Charlestown section of Boston, with close access to the region's prestigious teaching hospitals and global biotechnology hub. Products are expected to be available in the U.S. beginning September 1, 2017.
